Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/jbmr.4049 http://scihub22266oqcxt.onion/10.1002/jbmr.4049 C7273005!7273005 !32406536     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32406536 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Bone+Miner+Res 2020 ; 35 (6 ): 1009-1013 Nephropedia Template TP {{tp|p=32406536 |t=2020. Osteoporosis Management in the Era of COVID-19 |pdf=|usr=}}{{32406536 }} gab.com Text Osteoporosis Management in the Era of COVID-19 JO: J Bone Miner Res http://www.kidney.de/pget.php?&tw=1&pmid=32406536 #FOAvip Osteoporosis is a chronic condition that reflects reduced bone strength and an associated increased risk for fracture. As a chronic condition, osteoporosis generally requires sustained medical intervention(s) to limit the risks for additional bone loss, compromise of skeletal integrity, and fracture occurrence. Further complicating this issue is the fact that the abrupt cessation of some therapies can be associated with an increased risk for harm. It is in this context that the COVID-19 pandemic has brought unprecedented disruption to the provision of health care globally, including near universal requirements for social distancing. In this Perspective, we provide evidence, where available, regarding the general care of patients with osteoporosis in the COVID-19 era and provide clinical recommendations based primarily on expert opinion when data are absent. Particular emphasis is placed on the transition from parenteral osteoporosis therapies. It is hoped that these recommendations can be used to safely guide care for patients with osteoporosis until a return to routine clinical care standards is available. © 2020 American Society for Bone and Mineral Research. Twit Text FOAVip Osteoporosis Management in the Era of COVID-19 ????J Bone Miner Res http://www.kidney.de/pget.php?&tw=1&pmid=32406536 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32406536 #FOAvip English Wikipedia <ref>{{Cite pmid|32406536 }}</ref> Osteoporosis Management in the Era of COVID-19 #MMPMID32406536 Yu EW ; Tsourdi E ; Clarke BL ; Bauer DC ; Drake MT J Bone Miner Res 2020[Jun]; 35 (6 ): 1009-1013 PMID32406536 show ga Osteoporosis is a chronic condition that reflects reduced bone strength and an associated increased risk for fracture. As a chronic condition, osteoporosis generally requires sustained medical intervention(s) to limit the risks for additional bone loss, compromise of skeletal integrity, and fracture occurrence. Further complicating this issue is the fact that the abrupt cessation of some therapies can be associated with an increased risk for harm. It is in this context that the COVID-19 pandemic has brought unprecedented disruption to the provision of health care globally, including near universal requirements for social distancing. In this Perspective, we provide evidence, where available, regarding the general care of patients with osteoporosis in the COVID-19 era and provide clinical recommendations based primarily on expert opinion when data are absent. Particular emphasis is placed on the transition from parenteral osteoporosis therapies. It is hoped that these recommendations can be used to safely guide care for patients with osteoporosis until a return to routine clinical care standards is available. © 2020 American Society for Bone and Mineral Research. |*Coronavirus Infections/blood/complications [MESH] |*Pandemics [MESH] |*Pneumonia, Viral/blood/complications [MESH] |Absorptiometry, Photon [MESH] |Biomarkers/blood [MESH] |Bone Density [MESH] |Bone Density Conservation Agents/administration & dosage/adverse effects/therapeutic use [MESH] |COVID-19 [MESH] |Continuity of Patient Care [MESH] |Denosumab/adverse effects/therapeutic use [MESH] |Disease Management [MESH] |Drug Administration Schedule [MESH] |Estrogen Replacement Therapy/adverse effects [MESH] |Fractures, Spontaneous/prevention & control/therapy [MESH] |Home Care Services [MESH] |Humans [MESH] |Immunosuppression Therapy/adverse effects [MESH] |Osteoporosis/blood/diagnostic imaging/drug therapy/*therapy [MESH] |Raloxifene Hydrochloride/adverse effects/therapeutic use [MESH] |Recurrence [MESH] |Telemedicine [MESH] |Thrombophilia/chemically induced/etiology [MESH]Osteoporosis Management in the Era of COVID-19 (epmc).pdf DeepDyve Pubget Overpricing